A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

U.S. District Judge Mark Pittman in Fort Worth, Texas, reportedly upheld the U.S. Food and Drug Administration's (FDA) ...

A federal judge in Texas has upheld the U.S. Food and Drug Administration's decision to remove Novo Nordisk's blockbuster drugs Ozempic and Wegovy from the drug shortage list, rejecting a challenge ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

In a statement, a spokesperson for Ozempic manufacturer Novo Nordisk only said that the company has “been working closely ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

US chemical output slows, National Resilience consolidates operations, AstraZeneca partners with a Chinese firm, and more ...

"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...